ASCO 2019 | Atezolizumab for TNBC

Erika Hamilton

Erika Hamilton, MD, of the Sarah Cannon Research Institute, Nashville. TN, discusses the use of
atezolizumab for the treatment of triple-negative breast cancer (TNBC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics